This study shows that specific ratios of circulating sphingolipids to steroids can predict the risk of future asthma ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

In December 2021, the US Food and Drug Administration (FDA) approved Tezspire (tezepelumab-ekko; Amgen, Inc and AstraZeneca AB), a thymic stromal lymphopoietin (TSLP) blocker, for the add-on ...

Please provide your email address to receive an email when new articles are posted on . The addition of oral azithromycin to standard treatment improved asthma control and reduced exacerbations ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%. The findings, published today in ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

Treatment failures occurred in 74% and 45% of patients in the PRED and pooled BENRA groups, respectively, at 90 days. (HealthDay News) — Benralizumab can be used for the treatment of acute ...

PARIS — Pregnancy is a period of asthma instability; it entails an increased risk for exacerbations. While therapeutic de-escalation, if not the outright cessation of maintenance treatment, is common, ...

“Be wary of [SABA] overuse. It is for when the patient has poor control of their symptoms, but should not be used for routine treatment,” said Holmes, a general practitioner (GP) partner at The Park ...